Comparing oxytocin alternatives for postpartum hemorrhage prevention in vaginal and caesarean births: a systematic review and meta-analysis.
Oxytocin holds the spotlight in postpartum hemorrhage prevention, but researchers keep asking: are there better options? A new systematic review and meta-analysis tackled this head-on, stacking up oxytocin against alternatives like tranexamic acid (TXA), carbetocin, and misoprostol for both vaginal and cesarean births.
Arch Gynecol Obstet
by Devi S, Suryavanshi MR, Chandrababu R
“Comparing oxytocin alternatives for postpartum hemorrhage prevention in vaginal and caesarean births: a systematic review and meta-analysis. Devi S(1), Suryavanshi MR(2), Chandrababu R(3). Author information: (1)Department of Obstetrics and Gynecological Nursing, Symbiosis College of Nursing (SCON), Symbiosis International Deemed University (SIDU), Pune, 412115, India. drseetadevi1981@gmail.com. (2)Department of Obstetrics and Gynecology, The Pimpri Chinchwad Municipal Corporation (PCMC), YCM Hospital, Pune, India. (3)Department of Medical Surgical Nursing, Sri Ramachandra Faculty of Nursing, Sri Ramachandra Institute of Higher Education and Research (Deemed to Be University), Porur, Chennai, Tamil Nadu, 600116, India. BACKGROUND: In this systematic review and meta-analysis, we aimed to explore the availability of alternatives to oxytocin for preventing postpartum haemorrhage (PPH) during vaginal births (VB) and caesarean births (CB). METHODS: We followed the Cochrane guidelines for the review, and reported the results using the PRISMA guidelines. Using a thorough search strategy, we retrieved original articles from SCOPUS, PubMed, Web of Science, and the Cochrane Library from January 2015 to February 2025. We analyzed the RCTs to compare Tranexamic Acid (TXA), carbetocin, and misoprostol with oxytocin for preventing PPH in both vaginal and caesarean births. The review's protocol has been officially registered with PROSPERO under the identifier CRD420251002602. RESULTS: A meta-analysis of 20 trials showed no statistically significant difference in reducing blood loss during vaginal births (SMD = - 0.21; 95% CI - 0.62 to 0.19; I2 = 96%). However, contrasting results were observed in cesarean births (SMD = - 0.82; 95% CI - 1.49 to - 0.16; p = 0.02). Correspondingly, no statistically significant difference was found in the occurrence of PPH in vaginal births (OR = 0.80; 95% CI 0.53 to 1.21; I2 = 98%), while significant variances were detected in cesarean births (OR = 0.58; 95% CI 0.43 to 0.80; I2 = 21%). Hemoglobin variation was notably lower in both vaginal and cesarean births (SMD = - 0.32; 95% CI - 0.49 to - 0.16; I2 = 93%) and (SMD = - 0.90; 95% CI - 1.52 to - 0.27; I2 = 96%), respectively. CONCLUSION: Considering the substantial heterogeneity and mostly non-significant pooled results, the current findings should be viewed as indicative rather than conclusive. Further rigorous, well-designed randomized controlled trials are necessary to better define their effectiveness, optimize dosing, and identify patient groups most likely to benefit. © 2026. The Author(s). Conflict of interest statement: Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: Not applicable, as this is a review study.”
The team pulled data from 20 randomized controlled trials published over the last decade. They checked how well each compound did at reducing blood loss and the risk of postpartum hemorrhage.
Key findings:
For vaginal births, oxytocin and its alternatives performed about the same. No major difference in blood loss or postpartum hemorrhage rates.
For cesarean deliveries, the story changed. Alternatives—especially carbetocin and TXA—showed a stronger effect, with less blood loss and a lower risk of hemorrhage compared to oxytocin.
Hemoglobin drops were generally smaller with alternatives in both delivery types.
This meta-analysis didn’t find a clear winner for vaginal births. But the cesarean section results are hard to ignore. Still, the researchers flagged high variability between studies. Translation: these findings are a solid starting point, not the last word.
Oxytocin research continues to be a hot topic for anyone exploring postpartum care. Want to dig deeper or source research compounds for your own work? Check out the oxytocin page or browse the vendor directory.
The big takeaway: oxytocin alternatives are worth a closer look, especially in cesarean births. More well-designed trials are overdue. For now, the research community has plenty to explore.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.